Comment from Yale Collaboration for Regulatory Rigor Integrity, and Transparency (CRRIT)

Summary: The Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) urges the FDA to sunset the CNPV pilot program. They argue that the program is redundant with existing expedited pathways, lacks transparency in its selection process, and may compromise patient safety by prioritizing speed over rigorous scientific review.